WaveMan
WaveMan · Company
PRQR · Proqr Therapeutics N.V.
> Search tickers & screens ⌘K
LIVE
← All companies

PRQR ProQR Therapeutics (PRQR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001612940
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about PRQR

Insiders, 180 days
+$1.3M net bought
2 buyers

ProQR Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ProQR Therapeutics N.V. insiders bought a net $1.3M of stock across 5 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
de Boer Daniel Anton
Chief Executive Officer
BUY
2026-08-03 SECtraded 2026-07-31
200,000
$354.0K
-32.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 9, 2026.
  • -3.4% median (-3.4% mean) 90-day return after 2 previous buys.
  • The trade is 40.0% of the 500,000 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer de Boer Daniel Anton bought about $354.0K of PRQR on Jul 31, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Filius Bart
Director
BUY
2026-07-21 SECtraded 2026-07-17
150,000
$257.9K
-31.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 26, 2026.
  • The trade is 50.0% of the 300,000 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Filius Bart bought about $257.9K of PRQR on Jul 17, 2026; 1 other insider bought within 30 days.
de Boer Daniel Anton
Chief Executive Officer
BUY
2026-07-13 SECtraded 2026-07-09
150,000
$261.0K
-27.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 7, 2026.
  • The trade is 50.0% of the 300,000 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer de Boer Daniel Anton bought about $261.0K of PRQR on Jul 9, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
de Boer Daniel Anton
Chief Executive Officer
BUY
2026-07-08 SECtraded 2026-07-07
150,000
$238.5K
-29.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 150,000 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer de Boer Daniel Anton bought about $238.5K of PRQR on Jul 7, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Filius Bart
Director
BUY
2026-06-30 SECtraded 2026-06-26
150,000
$231.0K
-29.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 150,000 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Filius Bart bought about $231.0K of PRQR on Jun 26, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.3M over 180 days
+$354.0K over 90 days
more than 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.1% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
below 62% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PRQR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.0%12M
-56%-36%-17%+3%2025-102025-122026-022026-042026-062026-082026-10 2026-07-31 · de Boer Daniel Anton bought $354.0K2026-07-09 · de Boer Daniel Anton bought $261.0K2026-07-17 · Filius Bart bought $257.9K2026-07-07 · de Boer Daniel Anton bought $238.5K2026-06-26 · Filius Bart bought $231.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PRQR: institutional holders (13F)

13F holdings, latest reported quarter
FRANKLIN STREET ADVISORS INC /NC
150,000 sh
$279.0K

Congress trades in PRQR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PRQR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.3M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PRQR financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-30.1%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$42.2M-$27.8M-$27.7M-$64.2M
SEC XBRL, fiscal years, as known on 2026-10-28

PRQR Stock Sonar score 2/7 axes

Find similar shapesCompare
Insider conviction
85
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.3M · 90 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Risk and compliance
67
Inputs
  • Short interest, % of float+3.1% · 67 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PRQR filings, in plain words

Are ProQR Therapeutics insiders buying or selling PRQR?

In the 180 days to 2026-10-28, ProQR Therapeutics insiders were net buyers, a net $1.3M across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, ProQR Therapeutics insiders were net buyers of PRQR, a net $1.3M across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies